Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of cardiac glycoside compound and its synthesis method and application

A synthesis method and compound technology, applied in the field of medicine, can solve the problems of adverse reactions of normal cells and difficult to guarantee safety, and achieve the effect of strong anti-tumor effect in vivo, good safety and low toxicity

Active Publication Date: 2021-08-03
MACAU UNIV OF SCI & TECH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While many cardiac glycosides have anti-tumor effects, they will also cause relatively large adverse reactions to normal cells, and their safety is difficult to guarantee. Therefore, it has become the biggest obstacle to their clinical application in anti-cancer. Currently, there are only a few strong Cardiac glycosides can enter the clinical stage of antineoplastic drugs, so more research and development of cardiac glycosides are needed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of cardiac glycoside compound and its synthesis method and application
  • A kind of cardiac glycoside compound and its synthesis method and application
  • A kind of cardiac glycoside compound and its synthesis method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] This embodiment provides a cardiac glycoside compound 19-dihydrocalotoxin, which is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof;

[0032]

[0033] The synthetic method of this cardiac glycoside compound (19-dihydrocalotoxin) is:

[0034] Calotoxin (215 mg, 0.39 mmol) was dissolved in methanol (20 mL) precooled in an ice bath, solid sodium borohydride (52 mg, 1.3 mmol) was added in portions, and the above solution was stirred at room temperature for 2 hours. After detecting the complete disappearance of the reaction raw materials by TLC (chromatographic chromatography), add saturated NH 4 Aqueous Cl (6.5 mL) was used to quench the reaction. After methanol was recovered under reduced pressure, the aqueous solution was extracted with ethyl acetate (EtOAc), and after the organic solvents were combined, they were washed with brine (5 mL) successively, anhydrous Na 2 SO 4 Dry, filter, and recover the organic solvent under reduced ...

Embodiment 2

[0038] Cytotoxicity of cardiac glycoside compound 19-dihydrocalotoxin on tumor cell line T47D

[0039] Human breast ductal carcinoma cells T47D were cultured in DMEM complete medium, and the growth inhibitory effect of the cardiac glycoside compound 19-dihydrocalotoxin in Example 1 on T47D tumor cells was detected by MTT assay. The specific experimental procedure was as follows:

[0040] Cells in the logarithmic growth phase were planted in a 96-well plate, 5×10 per well 3 After the cells adhere to the wall, treat the cells with a series of different concentrations of drug-containing medium for 24 hours, set up three duplicate wells, and set up blank control wells and zero-adjustment wells at the same time, and then add 10 μL of 5 mg / mL to each well. After further incubation for 4 hours, the culture medium was removed, and 100 μL DMSO was added to each well to dissolve the formed formazan, and then the absorbance value was measured at a wavelength of 570 nm. The cell growth i...

Embodiment 3

[0047] Inhibitory Effect of Cardiac Glycoside Compound 19-dihydrocalotoxin on HIF-1α Protein Expression (Western Blotting Experiment)

[0048] In order to confirm whether the inhibitory effect of cardiac glycosides (19-dihydrocalotoxin) on HIF-1 transcriptional activity in Example 1 is caused by its inhibition of HIF-1 activity or reduction of HIF-1 protein expression, western blot experiments were used to detect representative Effects of cardiac glycosides on HIF-1α protein expression in tumor cells under hypoxic conditions. The T47D cells were planted in 6-well plates, and the cells were treated with different concentrations of cardiac glycoside-containing medium after adherence, and the cells were placed under hypoxic conditions for 24 hours, and normoxic conditions (oxygen concentration 21%) and Blank control wells under hypoxic conditions (oxygen concentration 1%). After the cell treatment, the cell protein was extracted, electrophoresis experiment and immunoblotting exp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of medicine, and discloses a cardiac glycoside compound, a synthesis method and application thereof. The cardiac glycoside compound is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof; the cardiac glycoside compound can achieve better tumor suppression effect and less toxicity to normal cells . The method for synthesizing the cardiac glycosides comprises the following steps: dissolving bocerin in a solvent, adding a reducing agent, and reacting at room temperature with stirring to synthesize the cardiac glycosides.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to a cardiac glycoside compound and its synthesis method and application. Background technique [0002] Cardiac glycosides are a class of drugs that selectively act on the heart and enhance myocardial contractility, also known as cardiac glycosides or cardiac glycosides. Related studies have shown that some cardiac glycosides can inhibit the growth of human tumor cells and induce their apoptosis (such as digoxin, etc.). While many cardiac glycosides have anti-tumor effects, they also have relatively large adverse reactions to normal cells, and their safety is difficult to guarantee. Therefore, it has become the biggest obstacle to their clinical application in anti-cancer. Currently, there are only a few strong Cardiac glycosides can enter the clinical stage of antineoplastic drugs, so more research and development of cardiac glycosides are needed. [0003] Therefore, the present invention...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07J71/00A61P35/00A61K31/7048
CPCA61P35/00C07J71/0005
Inventor 白丽萍郑植元周小波朱国元姜志宏
Owner MACAU UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com